



Company Name: Linical Co., Ltd.
Representative: Kazuhiro Hatano
President & CEO
(TSE code: 2183)

October 9, 2026

Notice Regarding Receipt of Large Orders

Linical Co., Ltd. (the Company) hereby announces that our Group has received Large Orders from our customer. Details are provided below.

These projects experienced delays in contract execution due to reduced operations at the FDA (U.S. Food and Drug Administration) following the partial shutdown of the U.S. government last year. While the effects of this situation continue to impact our order acquisition activities in the United States, the environment is gradually normalizing, and inquiries from prospective clients seeking to outsource development projects to the Company have been increasing. We will continue to actively pursue further business opportunities and work toward securing additional orders.

1. Order Details

- (1) Customer: U.S. biotechnology company
- (2) Order Amount: 20.4 million US Dollar (3,212 million yen)

2. Future Outlook

The impact of this matter on our financial results for the fiscal year ending March 31, 2027 has already been reflected in the consolidated financial forecast disclosed on May 15, 2026.

End

(Note)

This is a translation of the press release originally drafted in Japanese for the disclosure required in compliance with the TSE regulations.